With the rising global prevalence of type 2 diabetes mellitus, oral hypoglycaemic agents (OHAs) are increasingly used for glycaemic control. While their systemic side effects are well-documented, dermatological adverse reactions remain under-recognised. This narrative review compiles and analyses published evidence on the cutaneous manifestations associated with various classes of OHAs. Reported adverse events range from benign rashes to severe reactions such as Stevens–Johnson syndrome and bullous pemphigoid. Given the spectrum of dermatologic presentations, dermatologists must remain vigilant, especially in patients presenting with unexplained eruptions while on antidiabetic therapy. Early recognition and prompt management can mitigate morbidity and guide safer drug selection.
Begum et al. (Thu,) studied this question.